Inogen price to book ratio INGN
Market value divided by the book value of the company's net assets, since 2014.
- Today, Oct 23, 2026
- 1.1×
- 10-year median
- 1.9×
- Against its 10-year history
- 27th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 0.4× to 22.6×
- Peer median
- 2.4×
Inogen's price to book ratio is 1.1× as of Oct 23, 2026.
That is below its ten-year median of 1.9×, lower than on 73% of days in the last ten years.
Over that time it ranged from 0.4× in Oct 2023 to 22.6× in Sep 2018.
The median for 10 medical instruments and supplies stocks of a similar size is 2.4×.
Price to book ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.1× | 0.8× | 1.1× |
| 2025 | 0.9× | 0.8× | 1.5× |
| 2024 | 1.1× | 0.5× | 1.6× |
| 2023 | 0.6× | 0.4× | 1.7× |
| 2022 | 1.3× | 1.3× | 2.2× |
| 2021 | 2.0× | 1.8× | 5.0× |
| 2020 | 2.8× | 1.7× | 4.3× |
| 2019 | 4.4× | 2.8× | 11.2× |
| 2018 | 9.1× | 8.5× | 22.6× |
| 2017 | 11.2× | 8.0× | 11.7× |
| 2016 | 8.7× | 4.6× | 8.8× |
| 2015 | 6.1× | 5.0× | 8.3× |
| 2014 | 4.9× | 2.7× | 4.9× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Inogen's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| INGNInogen | 1.1× |
| PDEXPro DEX | 4.2× |
| UTMDUtah Medical Products | 1.9× |
| INFUInfuSystem | 4.7× |
| KEQUKewaunee Scientific | 1.3× |
| EMBCEmbecta | n/m |
| TCMDTactile Systems Technology | 2.4× |
| MDXGMimedx | 2.6× |
| APTAlpha Pro Tech | 0.9× |
| MOVMovado | 1.4× |
| NEPHNephros | 3.2× |
| Peer median | 2.4× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Inogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.